[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343012-105":59,"doc-detail-343012-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","loss-of-tumor-suppressors-promotes-inflammatory-tumor-microenvironment-and-enhances-lag3t-cell-mediated-immune-suppression","Loss of tumor suppressors promotes inflammatory tumor microenvironment and enhances LAG3+T cell mediated immune suppression","","Low response rate and treatment relapse remain major obstacles for cancer therapy using immune checkpoint blockade. The study reports that loss of specific tumor suppressors triggers an inflammatory program and remodels the tumor microenvironment into an immune-suppressive state. Using in vivo CRISPR/Cas9 loss-of-function screening, the work identifies NF1, TSC1, and TGF-β RII as regulators of immune composition and links their loss to altered chromatin accessibility and IL6-JAK3-STAT3/6 activation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/loss-of-tumor-suppressors-promotes-inflammatory-tumor-microenvironment-and-enhances-lag3t-cell-mediated-immune-suppression/343012/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/loss-of-tumor-suppressors-promotes-inflammatory-tumor-microenvironment-and-enhances-lag3t-cell-mediated-immune-suppression/343012.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which tumor suppressors were identified as regulators of immune composition?","Question",{"text":113,"@type":114},"NF1, TSC1, and TGF-β RII were identified as tumor suppressors that regulate immune composition via in vivo CRISPR/Cas9 loss-of-function screening.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What molecular pathways connect tumor suppressor loss to immune suppression?",{"text":118,"@type":114},"Loss of these tumor suppressors alters chromatin accessibility and enhances IL6-JAK3-STAT3/6 inflammatory pathways, producing an immune-suppressive tumor landscape.",{"name":120,"@type":111,"acceptedAnswer":121},"How does targeting LAG3 and PD-L1 affect tumor progression in the study?",{"text":122,"@type":114},"In preclinical triple-negative breast cancer mouse models with NF1-, TSC1-, or TGF-β RII-deficient tumors, simultaneous ICB targeting of LAG3 and PD-L1 inhibits metastatic progression.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},343012,1790469902,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article [https://doi.org/10.1038/s41467-024-50262-8](https://doi.org/10.1038/s41467-024-50262-8)  \nLoss of tumor suppressors promotesinﬂammatory tumor microenvironment and enhances LAG3+T cell mediated immune suppression  \nReceived: 27 March 2023  \n\n| Accepted: 2 July 2024 |\n| --- |\n| |\n| Check for updates |\n\nSara Zahraeifard1,6, Zhiguang Xiao1,6, Jae Young So1,6, Abdul Ahad1,  \nSelina Montoya1, Woo Yong Park1, Trinadharao Sornapudi1, Tiffany Andohkow1, Abigail Read1, Noemi Kedei2, Vishal Koparde 3,4, Howard Yang 1,  \nMaxwell Lee 1, Nathan Wong3,4, Maggie Cam3, Kun Wang 5, Eytan Ruppin 5  \n,  \nJi Luo 1, Christine Hollander1 & Li Yang 1   \nLow response rate, treatment relapse, and resistance remain key challenges for cancer treatment with immune checkpoint blockade (ICB). Here wereport that loss of speciﬁc tumor suppressors (TS) induces an inﬂammatory response and promotes an immune suppressive tumor microenvironment. Importantly, low expression of these TSs is associated with a higher expression of immune checkpoint inhibitory mediators. Here we identify, by using in vivo CRISPR/ Cas9 based loss-of-function screening, that NF1, TSC1, and TGF-β RII as TSs regulating immune composition. Loss of each of these three TSs leads to alterations in chromatin accessibility and enhances IL6-JAK3-STAT3/6 inﬂammatory pathways. This results in an immune suppressive landscape, characterized by increased numbers of LAG3+ CD8 and CD4 T cells. ICB targeting LAG3 and PD-L1 simultaneously inhibits metastatic progression in preclinical triple negative breast cancer (TNBC)mouse models of NF1-, TSC1-or TGF-β RIIdeﬁcient tumors. Our study thus reveals a role of TSs in regulating metastasis via non-cell-autonomous modulation of the immune compartment and provides proof-of-principle for ICB targeting LAG3 for patients with NF1-, TSC1-or TGF-β RII-inactivated cancers.  \nImmune checkpoint blockade (ICB) has recently emerged as a new treatment option for multiple cancer types. However, it is challenged by low response, treatment resistance/relapse, and a lack of biomarkers for patient stratiﬁcation1–3. Treatment failure and subsequent  \ntumor progression are orchestrated by dynamic and sophisticated tumor-host interactions involving alterations of both the tumor genome or epigenome and the immune microenvironment2,4,5. Immunogenomics analysis of more than 10,000 tumors across cancer types  \n1Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 2Collaborative Protein Technology Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 3Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 4Advanced Biomedical Computational Sciences, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USA. 5Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 6These authors contributed equally: Sara Zahraeifard, Zhiguang Xiao, Jae Young So. [e-mail:](e-mail: yangl3@mail.nih.gov)[ yangl3@mail.nih.gov](e-mail: yangl3@mail.nih.gov)  \nrevealed a correlation of genomic aberrations with different tumor immune landscapes6. Recently, single-cell and spatially resolved transcriptomics analysis deconvoluted data from large breast cancer cohorts and stratiﬁed them into nine ecotypes with unique cellular compositions and clinical outcomes7. In addition, loss of tumor suppressors (TS) such as PTEN, p53, and p73 alters the immune-cell composition8,9. Notably, loss of PTEN, in combination with p53 or ZBTB7a, resulted in a distinct immune-cell composition8. Of great interest, the adaptive immune system was found to be a major driver for tumor suppressor inactivation in in vivo CRISPR screens c","cbCaisE6JAge9JUx","https://ap.wps.com/l/cbCaisE6JAge9JUx","pdf",5683763,17,"English","# Background and challenge\n## Immune checkpoint blockade limitations\n## Tumor-host interactions and immune microenvironment\n# Study findings\n## Identifying tumor suppressors regulating immune composition\n## Mechanistic links to chromatin accessibility and IL6-JAK3-STAT3/6\n## Expansion of LAG3+ CD4 and CD8 T cells\n# Therapeutic implications\n## Dual targeting of LAG3 and PD-L1\n## Effects in triple-negative breast cancer models","[{\"question\":\"Which tumor suppressors were identified as regulators of immune composition?\",\"answer\":\"NF1, TSC1, and TGF-β RII were identified as tumor suppressors that regulate immune composition via in vivo CRISPR/Cas9 loss-of-function screening.\"},{\"question\":\"What molecular pathways connect tumor suppressor loss to immune suppression?\",\"answer\":\"Loss of these tumor suppressors alters chromatin accessibility and enhances IL6-JAK3-STAT3/6 inflammatory pathways, producing an immune-suppressive tumor landscape.\"},{\"question\":\"How does targeting LAG3 and PD-L1 affect tumor progression in the study?\",\"answer\":\"In preclinical triple-negative breast cancer mouse models with NF1-, TSC1-, or TGF-β RII-deficient tumors, simultaneous ICB targeting of LAG3 and PD-L1 inhibits metastatic progression.\"}]","Loss of tumor suppressors promotes inflammatory tumor microenvironment and enhances LAG3+T cell mediated immune suppression | PDF",1790049397,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a557ea11408238a9a9d494cc25da7568.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e6d491aeb95654154688a6f8250b6fd.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8d24ab8767ba0cbf6a45d0713641247.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d306b11142797ebf9ac3e554d4b3ea9.webp",980,1301]